Renal involvement in systemic lupus erythematosus (SLE) continues to be a major contributor to morbidity and mortality. Up to 50% of SLE patients will have clinically evident kidney disease at presentation; during follow-up, renal involvement will occur in >60% of patients, with an even greater representation among children and young adults.\(^1,2\) Lupus nephritis impact clinical outcomes in SLE both directly by target organ damage and indirectly through complications of therapy. Recent clinical studies of SLE patients with renal disease, including a number of randomized controlled treatment trials, have clarified the therapeutic role of a variety of immunosuppressive regimens both in proliferative and membranous lupus nephritis.\(^3\) The goal of each of these trials has been to achieve clinical efficacy with a remission of the nephritis while minimizing deleterious side effects of treatment.

Although lupus nephritis may affect all compartments of the kidney, glomerular involvement is the best-studied component and correlates well with the presentation, course, and treatment of the disease.\(^4\) The 2004 modifications in the current International Society of Nephrology (ISN)/Renal Pathology Society classification refine and clarify some of the deficiencies of the older World Health Organization (WHO) classification of lupus nephritis.\(^5\) The current approach to treating lupus nephritis—and studying new therapeutic modalities—has largely been guided by histologic findings by ISN class with appropriate consideration of presenting clinical parameters and degree of renal impairment.

CONSERVATIVE, NONIMMUNOMODULATORY THERAPY IS APPROPRIATE FOR CLASS I AND II LUPUS NEPHRITIS

ISN class I nephritis denotes normal glomeruli by light microscopy but presence of mesangial immune deposits on immunofluorescence and/or electron microscopy. ISN class II, mesangial proliferative lupus nephritis, is defined as pure mesangial hypercellularity (more than three mesangial cells in areas away from the vascular pole in 3-µm-thick histologic sections) by light microscopy with mesangial immune deposits.\(^5\) In general, patients with ISN class I and II require no therapy directed at the kidney. The majority of patients will have good long-term renal outcomes, and the potential toxicity of any immunosuppressive regimen will negatively alter the risk–benefit ratio of treatment. An exception is the group of lupus patients with minimal change syndrome or lupus podocytopathy,\(^6–8\) who respond to a short course of high-dose corticosteroids in a fashion similar to patients with minimal change disease.

Optimal control of BP through renin angiotensin aldosterone system (RAAS)
blockade is a cornerstone of conservative therapy in lupus nephritis. The National Kidney Foundation’s Kidney Disease Out- comes Quality Initiative guidelines recommend interruption of the RAAS with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers as first-line anti-hypertensive therapy in the management of proteinuric kidney dis-eases, including lupus nephritis. These drugs decrease intraglomerular pressure, lower systemic arterial BP, reduce urina-ry protein excretion, and delay the progression of chronic kidney disease to ESRD. A recent report from the lu- pus in minorities: nature versus nurture cohort suggests that ACE inhibitors de- lay the development of renal involve- ment in SLE. Eighty of 378 patients (21%) in the cohort used ACE inhibitors. The probability of renal involvement free-survival at 10 years was 88.1% for ACE inhibitor users and 75.4% for non-users (P = 0.01), and by multivariable Cox proportional hazards regression analyses, ACE inhibitors associate with a longer time-to-renal involvement occur- rence (hazard ratio, 0.27; 95% confi- dence interval, 0.09 to 0.78). ACE inhib- itor use also associates with a decreased risk of disease activity (hazard ratio, 0.56; 95% confidence interval, 0.34 to 0.94).

The RAAS, and its pharmacologic blockade, may play a role in the patho-genesis and prognosis of SLE indepen-dent of its effects on systemic BP and glo- merular hemodynamics. A number of animal studies have highlighted the in-flammatory components of the RAAS and the potential benefits of RAAS blockade in reducing or eliminating this inflammation in lupus nephritis. De Albuquerque et al. treated lupus-prone mice with cap- topril and found that captopril delays the onset of proteinuria when administered to prenephritic mice and slows progres-sion of disease in mice with early and ad- vanced lupus nephritis. These results were not seen in a control group treated with verapamil. The ACE inhibitor–in-duced improvement in renal disease cor-relates with reduced TGF-β expression, particularly of the TGF-β1 and TGF-β2 isoforms, in the kidneys. Moreover, in vivo or in vitro exposure to captopril re-duces splenic levels of IL-4 and IL-10, suggesting an effect of captopril on the immune system of treated animals. In a recent experiment on the effect of aldo-sterase blockade on the development and progression of glomerulonephritis in a murine model of lupus, spironola-c tone significantly reduces the incidence of nephritic range proteinuria and, on histology, showed far less severe glo- merular injury (no crescents, diminished overall cellularity, and less prominent deposits in the capillary loops and mesan-gium) compared with controls. The investiga-tors found significant differences in levels of anti-ssDNA and anti-dsDNA antibo-dies between control mice and mice treated with spironolactone by 36 weeks of age, again highlighting a potential anti-in-flammatory, immune-mediating compo-nent of RAAS blockade.

**MYCOPHENOLATE MOFETIL AND LOW-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE ARE SUITABLE ALTERNATIVES TO STANDARD MONTHLY INTRAVENOUS CYCLOPHOSPHAMIDE FOR INDUCTION PHASE TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS**

ISN class III, focal lupus nephritis, is de-fined as focal segmental and/or global endocapillary and/or extracapillary glo- merulonephritis affecting <50% of the sampled glomeruli. ISN class IV, diffuse lupus nephritis, has diffuse segmental and/or global endocapillary and/or extracapillary glomerulonephritis affecting ≥50% of glomeruli. Both class III and class IV may have active (proliferative), inactive (sclerosing), or combined active and inactive lesions subclassified as A, C, or A/C, respectively. Most patients with active proliferative lupus nephritis are initially treated with corticosteroids (traditionally a pulse of intravenous steroids followed by a high-dose oral regimen that begins to taper at 8 weeks) used in conjunction with other immunosup-pressive agents. Clinical trials in the last decade provide support for using myco-

Cyclophosphamide remains a reliable and effective treatment for inducing remission in lupus nephritis. Whether oral therapy or intravenous pulses of cyclophosphamide is more effective in treating lupus nephritis remains inconclu-sive, but intravenous therapy involves a lower cumulative exposure to cyclophos-phamide, less frequent cytopenias, en-ables enhanced bladder protection, and avoids problems of nonadherence. Randomized, controlled trials at the Na-tional Institutes of Health in patients with severe, proliferative lupus nephritis established that six pulses of intravenous cyclophosphamide (0.5 to 1 g/m²) on consecutive months, followed by every third month follow-up pulses with low-dose corticosteroids, was effective and prevented relapses better than a shorter regimen limited to six doses alone. A subsequent controlled trial established that pulse cyclophosphamide when given with monthly pulses of methyl-prednisolone led to better long-term GFR than either regimen alone. Nevertheless, side effects were significant in both therapeutic arms of this study and included ischemic and valvular heart disease, avascular necrosis, os-teoporosis, and premature menopause. Major infections occurred in 33% of subjects treated with cyclophospha-mide alone and 45% of subjects treated with cyclophosphamide plus steroids. Therefore, more recent studies using newer regimens focuses on achieving the high induction response rate of “National Institutes of Health proto-col” cyclophosphamide with fewer side effects.

A trial by the EuroLupus Group tried to decrease the risk of side effects from cyclophosphamide therapy without sacrificing efficacy. This study random-ized 90 patients with diffuse or focal proliferative lupus nephritis, or membranous plus proliferative disease, to receive either standard six monthly pulse of cyclophos-phamide (0.5 to 1 g/m²) followed by every
third monthly infusions or to a shorter treatment course consisting of 500 mg of intravenous cyclophosphamide every 2 weeks for six doses (total dose, 3 g), followed by azathioprine maintenance therapy (2 mg/kg per day). Both regimens were equally effective in various renal and extra-renal outcomes. The shorter regimen had less toxicity with significantly less severe and total infections as a complication of treatment. This trial was largely performed in white subjects and may not be applicable to all populations at high risk for poor renal outcomes. However, reports from this trial with up to 10 years of follow-up continue to find no differences in outcome between treatment groups.21

Several recent controlled trials, and subsequent meta-analyses, establish MMF as one of the recommended, first-choice regimens for inducing a remission in severe active proliferative lupus nephritis.22–27 An initial report was a Chinese study of 42 patients randomized to receive either 12 months of oral MMF (2 g/d for 6 months followed by 1 g/d for 6 months) or 6 months of oral cyclophosphamide (2.5 mg/kg per day), followed by oral azathioprine (1.5 mg/kg per day) for 6 months.22 Both groups received concomitant tapering doses of corticosteroids. At 12 months, the rate of complete remission (81 versus 76%), partial remission (14 versus 14%), and relapses (15 versus 11%) were not different between the regimens, but infections were less common in the MMF arm, and mortality was only seen in the cyclophosphamide group (0 versus 10%). Long-term follow-up of this population showed similar rates of chronic renal failure, defined as doubling of baseline creatinine, in the MMF group (6.3%) and the cyclophosphamide-azathioprine group (10.0%), as well as similar rates of relapse and relapse-free survival. However, infection was now significantly less in the MMF group (13 versus 40%), and mortality was still entirely in the cyclophosphamide group.25

A larger U.S. induction trial, reported 5 years later in a more diverse population (>50% African Americans), examined 140 patients with proliferative lupus nephritis or membranous lupus nephritis randomized to intravenous cyclophosphamide monthly pulses versus oral MMF up to 3 g daily, each in conjunction with a fixed tapering dose of corticosteroids as induction therapy over 6 months.24 Although the study was powered as a noninferiority trial, complete remissions and complete plus partial remissions at 6 months were significantly more common in the MMF arm (52%) than the cyclophosphamide arm (30%). Again, the side effect profile was better in the MMF group, and at 3 years, there were no significant differences in numbers of patients with renal failure, ESRD, or mortality. Most recently, a 370-patient, international multicenter trial of induction therapy with either MMF (3 g/day) or monthly intravenous cyclophosphamide pulses showed, after 6 months of therapy, virtually identical rates of achieving complete and partial remission (56.2% of patients receiving intravenous cyclophosphamide, \(P = 0.58; \) Figure 1).26 The groups proved identical with respect to improvement of renal function (assessed by GFR, serum creatinine, proteinuria, and urine sediment) and nonrenal parameters (reduction in anti-DNA antibody titers, normalization of serum complement, and increase in serum albumin). Notably, there was no difference in mortality between the groups, with a total of 14 deaths among the 370 patients. A subgroup analysis of those presenting with significant renal failure (defined as GFR < 30 ml/min) found no indication that MMF was less effective than cyclophosphamide in this setting. In contrast, azathioprine as induction therapy for lupus nephritis has not proven as effective as intravenous cyclophosphamide, with more relapses and less long-term benefit than cytotoxic therapy.28

Other agents have been explored in induction regimens, typically used in conjunction with MMF and/or steroids. Rituximab, an anti-CD20 monoclonal antibody that depletes B cells, is useful in inducing remissions in some patients with severe lupus nephritis, including those who have failed cyclophosphamide or MMF therapy.29,30 However, recent data from two randomized controlled trials in which rituximab or placebo were added to standard immunosuppressive regimens failed to show a benefit for rituximab in this setting. The Exploratory Phase II/III SLE Evaluation of Rituximab trial tested the efficacy and safety of rituximab versus intravenous cyclophosphamide.

\[\text{Figure 1. Rates of complete and partial remission in the Aspreva Lupus Management Study (ALMS) trial. After 6 months of therapy, induction therapy with either MMF or monthly intravenous cyclophosphamide pulses showed virtually identical rates of remission. In subgroup analyses by race, nonwhite and non-Asian subjects showed significantly higher rates of remission with MMF than cyclophosphamide. Reprinted from ref. 26.}\]
Rituximab versus placebo in 257 patients with moderately-to-severely active extrarenal SLE but without lupus nephritis. Background treatment was evenly distributed among azathioprine, MMF, and methotrexate. No differences were observed between placebo and rituximab in the primary and secondary efficacy endpoints. The Lupus Nephritis Assessment with Rituximab trial randomized 140 patients with severe lupus nephritis to rituximab or placebo added to a full dose of MMF (up to 3 g/day) and tapering doses of corticosteroids. Although more subjects in the rituximab group achieved complete remission or partial remission, there was no statistically significant difference in the primary clinical endpoint at 1 year. Although these results do not support the routine use of rituximab, the nature of their trial designs—adding rituximab to full, effective doses of conventional therapy in small numbers of patients studied for relatively short follow-up periods—may have contributed to the likelihood of negative results. Thus, the role of rituximab remains unclear in the treatment of lupus nephritis, but it may still be of use in treating resistant patients, preventing flares, or reducing the number or doses of other immunosuppressives.

Another induction treatment strategy studied in small settings is to combine a calcineurin inhibitor with MMF or azathioprine plus corticosteroids. This multigated immunosuppressant regimen is akin to those used in protecting kidney transplants. For example, Bao et al. randomized 40 patients with diffuse proliferative lupus nephritis superimposed on membranous lupus nephritis (ISN class IV + V) to induction therapy with MMF, tacrolimus, and steroids (multitarget therapy) or intravenous cyclophosphamide plus steroids. Intention-to-treat analysis showed a higher rate of complete remission with multitarget therapy at both 6 and 9 months (50 and 65%, respectively) than with cyclophosphamide (5 and 15%, respectively; Figure 2). Adverse events were lower in the multitarget group also.

Plasma exchange has been added to other cyclophosphamide induction therapy in several trials without any shown benefit in terms of renal or patient survival. Therefore, the routine use of plasma exchange is not justified in lupus nephritis, although this procedure may be of value in unique individuals such as those with a refractory anti-phospholipid antibody and contraindications to anti-coagulation or those with both positive lupus and ANCA serologies. For patients with life-threatening resistant disease, small pilot studies have used total lymphoid irradiation, and immunoablation by high-dose cyclophosphamide and anti-thymocyte globulin, with or without reconstitution with autologous stem cells. Although these approaches have led to some sustained, treatment-free remissions, they are potentially toxic and have significant treatment-related mortality. They have not been widely studied or embraced as therapy for lupus nephritis.

**MAINTENANCE PHASE TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS SHOULD USE THE LOWEST AND BEST-TOLERATED IMMUNOSUPPRESSIVE AGENT**

Once remission has been induced, maintenance phase therapy should focus on the long-term management of chronic, more or less indolent, disease. The goals of continued immunosuppressive therapy are to avoid relapse and flares of disease activity, to avoid smoldering activity leading to chronic irreversible renal scarring, and to prevent long-term side effects of therapy. A number of meta-analyses unequivocally favor the additional benefit of using an immunosuppressive agent (or agents) during the maintenance phase of lupus nephritis therapy. Given the risk for long-term toxicities with such agents, as well as their potential effect on fertility and risk for teratogenicity, the selection and dosage of maintenance therapy is an important and modifiable choice that doctor and patient should make together.

Corticosteroids remain a major component of treatment in the maintenance phase of lupus nephritis therapy, and there are no clinical studies that exclude the use of steroids in maintenance therapy. However, to minimize the side effects of long-term steroids, the dosage should be limited, and osteoporosis prophylaxis should be given concomitantly; many clinicians will have their lupus nephritis patients off steroids within the first 1 to 6 months of maintenance therapy despite a lack of trial data for such a strategy. Although both intravenous and oral cyclophosphamide have been used for maintenance therapy in a number of trials, their use for >3 to 6 months of maintenance should be avoided because
of toxicities, which include alopecia, hemorrhagic cystitis, bladder cancer, gonadal damage, and early menopause.

Both azathioprine and MMF show efficacy in maintaining remission and preventing relapses in patients with lupus nephritis. These agents are superior to continued intravenous cyclophosphamide in both preventing lupus nephritis flares and maintaining kidney function. Of equal importance, these agents show significantly lower rates of long-term toxicity, including an approximately 80% lower risk for amenorrhea and 65 to 70% lower risk for infection. The equivalence of MMF and azathioprine for maintenance was most recently shown in results from the MAINTAIN Nephritis Trial (A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-Maintenance Treatment for Proliferative Lupus Glomerulonephritis) which are currently available in abstract form.

In this randomized, open-label trial, after induction therapy with intravenous cyclophosphamide (Euro-Lupus protocol), 105 subjects with class III (31%), IV (58%), or V (10%) lupus nephritis were given either azathioprine (mean maximum daily dose, 124 mg) or MMF (mean maximum daily dose, 2.0 g) maintenance therapy and followed for at least 3 years. The rates of all primary and secondary endpoints—including remission, steroid withdrawal, and disease flares—were equal among both groups. In contrast, results of the Aspreva Lupus Management Study (ALMS) maintenance phase, also currently in abstract form, were notable for superior renal benefits (in time to treatment failure and renal flare) with MMF versus azathioprine.

Azathioprine, in doses of 1 to 2.5 mg/kg per day, has proven remarkably safe over much longer periods of follow-up. Macrocytosis, leukopenia at high doses, and interaction with allopurinol (limiting its use in patients with gout) are all potential side effects, along with the ever-present risk of infection from immunosuppression. Nevertheless, azathioprine has only a small oncogenic potential, and pregnancy during maintenance azathioprine is relatively safe compared with a number of other immunosuppressive agents. Although MMF has a similarly favorable, long-term toxicity profile, it should not be used during pregnancy. Given that many patients with lupus nephritis are women of childbearing age, this difference in therapies can help individualize therapy in some patients.

**MMF, WITH OR WITHOUT A CALCIUNIN INHIBITOR, IS EFFECTIVE THERAPY FOR CLASS V (MEMBRANOUS) LUPUS NEPHRITIS**

Class V, or membranous, lupus nephritis is defined by subepithelial immune deposits. The membranous alterations may be present alone or on a background of mesangial hypercellularity and mesangial immune deposits. Investigators report very different renal survival rates for different populations with membranous lupus nephritis. These differences were, in part, caused by problems with the WHO classification, which included proliferative lesions superimposed on pure lupus membranous nephropathy (WHO classes Vc and Vd) along with those with only predominantly pure membranous features (Va and Vb). In addition, patients with subnephrotic proteinuria and pure membranous lupus nephritis do extremely well regardless of treatment options, and no consensus of management has emerged yet for this group of patients, who may not require any specific therapy beyond RAAS blockade.

Most treatment regimens studied for pure membranous lupus nephritis with nephrotic range proteinuria are based on successful therapies used for idiopathic membranous nephropathy. For example, Austin et al. randomized 42 patients with membranous lupus nephritis to three groups: cyclosporine for 11 months (on top of steroids), alternate-month intravenous pulse cyclophosphamide for six doses (also on top of steroids), and alternate-day prednisone alone. At 1 year, the cumulative probability of remission was 27% with prednisone, 60% with cyclophosphamide, and 83% with cyclosporine. Remissions occurred more quickly in the cyclosporine group, but there were fewer relapses in the cyclophosphamide group.

Similar data are available from small numbers of patients treated with tacrolimus monotherapy. Two recent trials of MMF versus intravenous cyclophosphamide induction in lupus nephritis included 84 patients with pure membranous lupus nephritis among the 510 patients enrolled. In a pooled analysis of these participants, remissions, relapses, and overall clinical course were similar in the membranous patients treated with oral MMF and intravenous cyclophosphamide induction therapy (Figure 3).

The previously discussed study by Bao et al., in which MMF was combined with a calcineurin inhibitor, lays out yet another potentially useful treatment regi-

---

**Figure 3.** In pooled analyses, MMF was equivalent to cyclophosphamide (IVC) in inducing remission for patients with class V lupus nephritis. Data from ref. 50.
men for cases of class V lupus nephritis associated with class IV proliferative lesions.

Thus, for patients with membranous lupus nephritis with nephrotic range proteinuria, there are multiple treatment options including a course of oral cyclosporine or tacrolimus, monthly intravenous pulses of cyclophosphamide, oral MMF, or oral azathioprine plus corticosteroids. Given the higher likelihood of relapse with calcineurin inhibitors and the potential, over the long term, for nephrotoxicity with these agents, MMF may emerge as the preferred induction and maintenance therapy for class V lupus nephritis. However, this will need to be proven in larger controlled randomized trials.

**NEWER AGENTS FOR LUPUS NEPHRITIS WILL BE TESTED IN COMBINATION WITH STANDARD OF CARE THERAPIES**

A number of new, immunomodulatory agents are currently being studied to improve outcomes in lupus nephritis, principally class III and IV proliferative lupus nephritis. As is the case with rituximab, these agents are being studied as additive therapy on top of induction regimens that are now considered standard of care, either MMF or intravenous cyclophosphamide. Ocrelizumab, a fully humanized anti-CD20 monoclonal antibody, was evaluated as adjunctive induction therapy in the Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus. Rituximab, a chimeric half murine-half human anti-CD20 monoclonal antibody, has been associated with the development, in approximately 10% of treated patients, of human anti-chimeric antibodies that are of uncertain significance. These antibodies have the potential to block the efficacy of future doses of rituximab. The design of Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus was based, in part, on the hope that ocrelizumab would have better outcome and safety profiles than rituximab because of the absence of human anti-chimeric antibody formation; however, the trial was stopped prematurely because of more serious and opportunistic infections than expected in recipients of ocrelizumab than placebo.

Abatacept, a selective T-cell co-stimulation modulator, is approved for use in adult rheumatoid arthritis and juvenile idiopathic arthritis. T-cell activation, a crucial step in the pathogenesis of glomerulonephritis, requires both binding of the T-cell receptor to the antigen–MHC complex on the antigen presenting cell and a costimulatory signal provided by the binding of the CD28 protein (on the T cell) to the B7 protein (on the antigen presenting cell). Abatacept binds to the B7 protein, preventing this costimulatory signal and, consequently, activation of T cells. Two current clinical trials—one sponsored by a pharmaceutical company (Bristol-Myers Squibb) and one funded by the National Institute of Allergy and Infectious Diseases—are exploring the use of abatacept in lupus nephritis as add-on induction therapy to the Euro-Lupus cyclophosphamide regimen or MMF.

Belimumab is a fully human monoclonal antibody that binds to soluble B-lymphocyte stimulator. The biologically active form of B-lymphocyte stimulator contributes to B-cell proliferation and differentiation, and thus belimumab is currently being studied as another anti-B-cell therapy with potential benefit for patients with SLE. Early phase trials with belimumab in patients with SLE showed efficacy in reducing levels of peripheral B cell but have yet to show this B-cell depletion translates into serologic (antibody levels) or clinical (lupus activity scores or, in patients with lupus nephritis, markers of renal function) improvements.

In case reports from Europe, adrenocorticotropic hormone (ACTH) shows promising results in patients with nephrotic syndrome of various etiologies, including membranous nephropathy, membranoproliferative glomerulonephritis, minimal change disease, and focal segmental glomerulosclerosis. In a randomized trial in idiopathic membranous nephropathy conducted by Ponticelli et al., ACTH and cyclophosphamide achieved equal rates of disease remission. Acthar gel, an ACTH formulation available in the United States with Food and Drug Administration approval for treating resistant nephrotic syndrome and SLE, may emerge as another potential treatment option for lupus nephritis, particularly class V lupus nephritis. Clinical trials are currently being planned to explore this route of therapy.

Laquinimod, also known by the laboratory codes TV-5600 or ABR-215062, is a quinoline-3-carboxamide derivative. This oral immunomodulator shows therapeutic benefits in various animal models of autoimmune disease, including SLE, and is currently being studied for treatment of lupus nephritis in humans. Although the exact mechanism of action of laquinimod is unknown, in animal models, the drug reduces leukocyte infiltration into target tissues (glomeruli in SLE and optic nerves in multiple sclerosis), downregulates MHC class II gene expression (and hence antigen presentation), and modulates cytokine balance.

**CONCLUSION**

The last decade has seen a tremendous amount of new data from well-conducted studies on how to best treat lupus nephritis by achieving favorable outcomes with the least amount of therapy-associated toxicities. However, the disease burden of lupus nephritis remains large, particularly among young women, and hence new therapies, or new regimens based on old therapies, are still actively being sought. The treatment of lupus nephritis today is markedly different, and objectively more effective, than it was 10 years ago. The hope and expectation is that a similar claim will be made 10 years hence.

**ACKNOWLEDGMENT**

This manuscript was supported, in part, by The Glomerular Center at Columbia University Medical Center and Zo’s Fund for Life.
DISCLOSURES

Drs. Bomback and Appel have received research support from Genentech, Roche, Aspreva-Vifor, Novartis, Teva, Alexion, and Questcor. Dr. Bomback has served as a consultant for Novartis and Questcor. Dr. Appel has served as a consultant for Genentech, Roche, Bristol-Myers Squibb, Teva, and Questcor.

REFERENCES


